Delcath Systems, Inc. is a pharmaceutical and medical device company, which focuses on oncology and liver cancer therapy. It develops and commercializes Melphalan Hydrochloride for Injection, which is a proprietary product for use with the Delcath Hepatic Delivery System. It is designed to administer concentrated regional chemotherapy to the liver. The company was founded on August 5, 1988 and is headquartered in New York, NY.
